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SUMMARY
What is known and objectives: Little is known about the ability
of community pharmacists who are inexperienced in medication
review to identify drug-related problems (DRPs). The objective
of our study was to investigate the completeness of DRPs in
terms of number, type and clinical relevance identified by
community pharmacists when performing home medication
reviews (HMRs).
Methods: This is a cross-sectional study within the intervention
arm of a randomized controlled trial among community-
dwelling patients (≥65 years, ≥5 drugs) in ten Dutch community
pharmacies. Community pharmacists, who were inexperienced
in medication review, received 2-day training in medication
review. These pharmacists interviewed patients at home about
their medicines, identified potential DRPs and made recom-
mendations in combination with medication and clinical
records. Expert reviewers completed the number of potential
DRPs and recommendations by reviewing all available infor-
mation, including patient interview reports.
Results and discussion: In 155 patients, community pharmacists
identified a mean of 36 (SD 28) potential DRPs per patient and
expert reviewers added 65 (SD 32) DRPs. Community pharma-
cists formulated 26 (SD 23) recommendations per patient and
reviewers added 75 (SD 33) recommendations. Community
pharmacists identified a higher proportion of clinically relevant
DRPs compared with expert reviewers, as assessed by DRPs
with high priority [OR = 18 (95% CI 14–22)], DRPs associated
with recommendations for drug change [OR = 19 (95% CI 15–
23)] and implemented recommendations for drug change
[OR = 21 (95% CI 16–27)].
What is new and conclusion: This study shows that the complete-
ness of medication reviews by inexperienced community phar-
macists with limited training could be improved, although they
identified a higher proportion of potentially clinically relevant
DRPs compared with expert reviewers. The results suggest that
community pharmacists with limited experience in medication
review may need more intensive post-graduate training.
WHAT IS KNOWN AND OBJECTIVES
Several randomized controlled trials (RCTs) have demonstrated
that clinical medication review can resolve drug-related problems
(DRPs). However, these RCTs differed in the expertise of partic-
ipating pharmacists who were either highly trained1–10 or inexpe-
rienced in medication review.11–13 Medication review is a complex
intervention, which requires both knowledge and skills.14,15
Medication review skills have to be developed to explore patient’s
experiences and beliefs about medicines, to identify potential
drug-related problems (DRPs), formulate recommendations for a
pharmaceutical care plan and to discuss this care plan with
physicians.15
No extensive post-graduate courses in medication review were
available at the start of this RCT on home medication review
(HMR) in the Netherlands.16 Therefore, community pharmacists,
who were inexperienced in medication review, received a two-day
training course as a part of this study where pharmacists were
taught on pharmacotherapy and medication review skills. As part
of the intervention, pharmaceutical care plans by the community
pharmacists were evaluated by independent expert reviewers.16
Relatively little is known to what extent community pharma-
cists are able to identify DRPs in medication review.17,18 In
particular, no research has been performed into the clinical
relevance of these DRPs. The objective of this study was to
investigate the completeness of DRPs in terms of number, type and
clinical relevance identified by community pharmacists in HMRs.
METHODS
Study design
This is a cross-sectional study among 155 community-dwelling
patients (≥65 years and ≥5 drugs including at least one cardiovas-
cular or one antidiabetic drug) enrolled in the intervention arm of
an RCT on HMRs in ten community pharmacies.
Intervention
Community pharmacists who were inexperienced in medication
review received 2 days of additional training. Pharmacists had
access to the patient’s medication records from the pharmacy,
which are generally a comprehensive source of information as the
majority of patients in the Netherlands are registered at only one
community pharmacy, independently of prescriber.19 Medical
history and laboratory data of the patient were collected with
the help of the GP practice. As part of the study protocol, patients
were offered additional laboratory measurements of HbA1c,
cholesterol, sodium, potassium and creatinine and blood pressure
measurement. Pharmacists interviewed patients at home about
their medicines, identified potential DRPs and made recommen-
dations in pharmaceutical care plans. Subsequently, expert
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reviewers (A.F., J.K.-D. and H.K.) completed the number of
potential DRPs and recommendations by reviewing all available
information, including patient interview reports. Expert reviewers
had several years of experience with medication review as well as
in-depth knowledge of national clinical guidelines. More details
about the intervention have been described elsewhere.16
Data collection and classification
Data extracted from the completed pharmaceutical care plans
included medication and medical information, patient interview
reports, identified potential DRPs and associated recommenda-
tions as well as the prioritization for implementation (high,
medium or low). Complete patient medication records from the
community pharmacy including drug-dispensing records until at
least 6 months after the patient interview were collected sepa-
rately.
Each potential DRP and recommendation were classified as
being identified by community pharmacist or added during
completion by pharmacist reviewer. When the description of a
DRP or recommendation was incomplete and refined by a
pharmacist reviewer, this DRP was assigned to the community
pharmacist. All potential DRPs and associated recommendations
were classified using the D.O.C.U.M.E.N.T. classification system
using the most recent version.16,20,21 Clinical relevance was
assessed by the percentage of DRPs assigned a high priority, the
percentage of recommendations for drug change and the percent-
age of implemented recommendations for drug change. Imple-
mented recommendations for drug change were assessed by
analysing drug-dispensing records for medication changes.
All coding and classification was independently undertaken by
one investigator (H.K.) and a student investigator (Y.A.). When
there were differences in coding, the investigators reached
consensus in a case conference with a third investigator (A.F. or
M.B.).
Statistical analysis
Pearson chi-squared tests were used to compare categorical
variables. Independent t-tests were used to compare the mean
number of DRPs per patient. Differences between the percentages
of clinically relevant DRPs and recommendations identified by
community pharmacists and those added by expert reviewers
were compared by odds ratios (ORs) and corresponding 95%
confidence intervals.
A P-value <005 was considered statistically significant. All data
were analysed using Microsoft Access 2007 (Microsoft Corpora-
tion, Redmond, WA, USA) and SPSS version 17.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
Identified DRPs and recommendations
During the study period, 16 different community pharmacists in
10 community pharmacies were involved. Community pharma-
cists identified 553 potential DRPs (mean 36, SD 28 per patient)
and expert reviewers 1012 potential DRPs (mean 65, SD 32 per
patient; Table 1). Community pharmacists formulated 398 recom-
mendations (mean 26, SD 23 per patient) and expert reviewers
1167 recommendations (mean 75, SD 33 per patient, P < 001;
Table 2). Considerable variations were observed in the proportion
of DRPs identified by community pharmacists (range 13–57%) and
recommendations formulated by community pharmacists (range
10–46%).
All DRP types, except ‘Compliance’, were in absolute numbers
more frequently added by expert reviewers. DRP types ‘Toxicity’
(P < 001) and ‘Undertreated’ (P = 004) were relatively more
frequently identified by community pharmacists (Table 1).
All recommendations were in absolute numbers more fre-
quently added by expert reviewers, except ‘Drug formulation
change’. ‘Addition of drug’ was relatively more frequently
recommended by community pharmacists (P = 002) (Table 2).
DRPs identified in patient interviews
Of 415 potential DRPs originating from patient interviews,
community pharmacists identified 171 DRPs (mean 11 per patient,
SD 11) and expert reviewers added 244 DRPs (mean 16 per
patient, SD 17) (P < 0. 01). ‘No indication apparent’ (n = 64, 26%),
‘Condition undertreated’ (n = 33, 14%), ‘Toxicity, allergic reaction
or adverse effect present’ (n = 30, 12%) and ‘Incorrect or unclear
dosing instructions’ (n = 29, 12%) were the main DRP subtypes
added by expert reviewers from patient interviews.
Clinical relevance
Community pharmacist identified a higher proportion of DRPs
with a high priority compared with expert reviewers [OR 18
(14–22), P < 001]. Furthermore, a higher proportion of DRPs
followed by recommendations for a drug change was identified by
community pharmacists compared with expert reviewers [OR 19
(15–23), P < 001]. Finally, a higher proportion of DRPs followed
by implemented recommendations for drug change was identified
by community pharmacists [OR 21 (16–27), P < 001] (Table 3).
DISCUSSION
This study shows that expert reviewers identified considerably
more potential DRPs and associated recommendations than
community pharmacists. However, the DRPs identified by com-
munity pharmacists were more often clinically relevant compared
with DRPs added by expert reviewers.
Expert reviewers almost doubled the amount of DRPs identified
by community pharmacists. The highest difference was seen for
the DRP type ‘Monitoring’. Reviewers especially added DRPs
related to appropriate monitoring of hypertension, dyslipidaemia,
diabetes22,23 and other diseases. Community pharmacists rarely
identified these. Monitoring-related problems accounted for more
than two DRPs per patient, but were mostly assigned a low
priority and not followed by a recommendation for drug change.
Monitoring-related problems and some other DRPs identified by
expert reviewers might be perceived by community pharmacists
and GPs as too theoretical or ‘textbook advice’.24 This may partly
explain why community pharmacists identified a lower number
but relatively more clinically relevant DRPs. Furthermore, com-
munity pharmacists may have ignored other potential DRPs,
expecting that associated recommendations might not be imple-
mented based on their earlier experiences with GPs and patients.
There was a considerable variation in the completeness of the
reviews. We were not able to identify explicit indicators that may
account for this variation in identified DRPs among pharmacists.
All participating community pharmacists had no previous hospital
experience, no additional clinical pharmacy skills nor followed
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earlier courses in medication review. Nevertheless, differences in
knowledge of pharmacotherapy and medication review skills14,15
among community pharmacists were observed by expert review-
ers. Furthermore, some pharmacists may have relied on the expert
reviewers to complete the medication reviews. This may partly be
explained by the fact that the registration of all research data was
experienced as time-consuming by the participating pharmacists.
Surprisingly, a considerable part of issues that were discussed
with the patients were not formally identified as potential DRP by
community pharmacists. The most frequently added subtype of
DRP by expert reviewers from patient interviews was ‘Indication
not apparent’. This refers to patients using drugs without knowing
the indication, which was also lacking in the GP record, or refers to
patients using drugs not intended for prolonged use. ‘Condition
undertreated’ was also frequently added by reviewers (e.g.
patients indicated that their pain treatment was suboptimal,
whereas community pharmacists had not suggested a change of
drug or dosing regimen). Furthermore, adverse effects were
frequently described in patient interview reports, but surprisingly
not always identified as potential DRPs. Possibly, community
pharmacists did not recognize complaints as caused by adverse
effects or did recognize these, but considered these as inevitable.
Finally, ‘Incorrect or unclear dosing instructions’ was also fre-
quently ‘missed’ as potential DRPs by community pharmacists.
Community pharmacists may consider these medication manage-
ment problems (e.g. time of intake) as typical pharmacist issues
and of minor interest for discussion with GP. Often, these issues
were directly solved during the patient interview by advice (e.g.
change time of intake).
The percentage of identified DRPs by community pharmacists
in our study (36%) was comparable to findings of Krska and
Avery17 (34%) with a clinical pharmacist and an experienced GP as
expert reviewers. In the study of Krska, training of the community
pharmacists was limited to 2 days, specifically designed for the
study, and no formal assessment of their competency to conduct
medication reviews was made.17 Laaksonen et al.18 investigated
the performance of community pharmacists who completed a
more intensive post-graduate course (i.e. five 60-h distance
learning modules in clinical therapeutics). These trained commu-
nity pharmacists managed to identify 75% of the DRPs found by a
clinical pharmacist. These comparisons with our study suggest
that 2-day training in medication review may be too limited. A
practical solution could be to enrol pharmacists inexperienced in
medication review in an intensive post-graduate course in which
feedback on reviews from expert reviewers (and portfolio build-
ing) plays an essential role.
This study had several strengths. First, a very detailed and
accurate description of DRPs was available, because community
pharmacists sent all pharmaceutical care plans to the expert
reviewers. This enabled us to distinguish very clearly between
Table 1. Comparison of number and type of drug-related problems (DRPs) identified by community pharmacists and added by expert
reviewers for 155 patients
DRP type and subtype
Community pharmacists Expert reviewers
P-
valueN %a N %a
Overall 553 36 1012 64 –
Mean per patient  SD 36 28 65 32 –
D(rug selection) 156 36 279 64 079
Duplication 7 58 5 42 009
Drug interaction 5 33 10 67 087
Contraindications apparent 28 38 46 62 065
No indication apparent 106 33 217 67 029
Other drug selection problem 10 91 1 9 <001
O(ver or underdose) 64 38 105 62 047
Prescribed dosage too high 14 42 19 58 039
Prescribed dosage too low 31 43 41 57 016
Incorrect or unclear dosing instructions 19 30 45 70 033
C(ompliance) 52 54 44 46 <001
Taking too little 25 58 18 42 <001
Taking too much 5 63 3 38 011
Difficulty using dosage form 22 49 23 51 005
U(ndertreated) 159 40 243 60 004
Condition undertreated 117 40 172 60 004
Condition untreated 28 36 49 64 085
Preventive therapy required 14 39 22 61 065
M(onitoring) 75 21 284 79 <001
Laboratory monitoring 58 22 203 78 <001
Non-laboratory monitoring 17 17 81 83 <001
E(ducation) or Information 1 11 8 89 013
Disease management or advice 1 11 8 89 013
T(oxicity) 46 48 49 52 <001
Toxicity, allergic reaction or adverse effect present 46 48 49 52 <001
DRPs, drug-related problems; SD, standard deviation.
a% is the percentage within type or subtype of recommendation.
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DRPs identified by community pharmacists and expert reviewers
and also provided insight into the clinical relevance of DRPs.
Second, the availability of detailed patient interview reports
enabled us to assign DRPs originating from patient interviews.
There are some limitations associated with this study. First,
expert reviewers in this study could only refine or add to the DRPs
already identified by community pharmacists. Blinding of the
reviewers for DRPs identified by community pharmacists would
have enabled a more in-depth comparison between community
pharmacists and expert reviewers. However, assuming that expert
reviewers would have identified the majority of DRPs detected by
community pharmacists, this would not have a major impact on
the findings of the study. Second, expert reviewers were depen-
dent on the provided documentation by community pharmacists
for identifying DRPs and did not conduct patient interviews. On
the one hand, expert reviewers at distance might have identified
some potential DRPs in this study that they possibly might have
neglected if they knew the patient. On the other hand, expert
reviewers might have identified more or other DRPs from patient
interviews. Third, the number of DRPs identified by community
pharmacists may have been underestimated, as a limited number
of issues were directly solved during the patient interview, but not
registered in the pharmaceutical care plan by the pharmacists.
WHAT IS NEW AND CONCLUSION
This study shows that the completeness of medication reviews by
inexperienced community pharmacists with limited training could
be improved, although they identified a higher proportion of
potentially clinically relevant DRPs compared with expert review-
Table 2. Comparisons of number and type of recommendations identified by community pharmacists and added by expert reviewers for
155 patients
Type of recommendation
Community Pharmacists Expert Reviewers
P-valueN %a N %a
Overall 398 25 1167 75 –
Mean per patient  SD 25 23 75 33 –
Recommendation for drug change 272 30 633 70 <001
Cessation of drug 59 29 146 71 024
Dose increase 31 32 67 68 015
Dose decrease 16 25 47 75 099
Addition of drug 85 31 190 69 002
Replacement of drug 49 30 115 70 017
Dose frequency/schedule change 20 27 54 73 075
Drug formulation change 12 50 12 50 <001
Recommended dose administration aid 0 0 3 100 031
Other recommendations 126 19 534 81 <001
Education/counselling session 10 20 39 80 041
Monitoring: Non-laboratory 14 14 85 86 <001
Monitoring: Laboratory 59 20 232 80 003
Adjustment of patient records 38 19 158 81 004
Other 4 17 19 83 037
SD, standard deviation.
a% is the percentage within type or subtype of recommendation
Table 3. Comparison of clinical relevance of drug-related problems (DRPs) identified by community pharmacists and added by expert
reviewers
Clinical relevance of DRPs
Community
Pharmacists Expert Reviewers
OR (95% CI) P-valueN % N %
Overall (reference) 553 100 1012 100 Ref –
With high priority 285 52 379 37 18 (14–22) <001
With recommendations for drug change 375 68 530 52 19 (15–23) <001
With implemented recommendations for drug change 132 24 133 13 21 (16–27) <001
OR, odds ratio; 95% CI, 95% confidence interval.
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ers. This suggests that a 2-day training programme in medication
review may be too limited.
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